You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Moderna's Covid vax more effective against Delta than Pfizer, J&J: Study

Moderna's vaccine for Covid-19 is significantly more effective against the Delta variant of the SARS-CoV2 virus than Pfizer or Johnson & Johnson, suggests a new study.

Topics
Coronavirus Vaccine

IANS  |  New York 

Moderna Covid-19 vaccine

Moderna's vaccine for Covid-19 is significantly more effective against the Delta variant of the SARS-CoV2 virus than Pfizer or Johnson & Johnson, suggests a new study.

The study, published in Morbidity and Mortality Weekly Report, suggests that Moderna was 95 per cent effective at preventing hospitalisation among adults ages 18 and older.

"These real-world data show that vaccines remain highly effective at reducing Covid-19 related hospitalisation and emergency department visits, even in the presence of the new Covid-19 variant," said researcher Shaun Grannis from Indiana University in the US.

"We strongly recommend vaccinations for all who are eligible to reduce serious illness and ease the burden on our healthcare system," Grannis added.

The team also found that Pfizer was 80 per cent effective at preventing hospitalisation among adults ages 18 and older. While Johnson & Johnson was 60 per cent effective.

For the study, the team analysed more than 32,000 medical encounters from nine states during June, July and August 2021, when the Delta variant became the predominant strain.

The results showed that unvaccinated individuals with Covid-19 are 5-7 times more likely to need emergency department care or hospitalisation, similar to the overall effectiveness prior to the variant.

The study also found that vaccine effectiveness is lower for people 75 years and older, which has not been shown in previous research.

This could be due to a range of factors, including the increased time since vaccination, the researchers noted.

--IANS

vc/in

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, September 11 2021. 11:03 IST
RECOMMENDED FOR YOU